B. Achieves double the weight loss of a SGLT2 inhibitor alone 

C. Is additive with respect to its effects on weight loss. 

A small retrospective observational study from the United Kingdom identified 122 diabetic patients from medical records and analyzed the 88 who had data on weight loss. Slightly over half of these (48 patients) were on dapagliflozin alone and the rest (40 patients) were on combination therapy with a GLP-1 agonist. Since GLP-1 agonists are insulin dependent and SGLT2 inhibitors are insulin independent, these drugs may be acting via independent, additive mechanisms to lead to weight loss. With a mean duration of follow-up the mean weight change with dapafliflozin alone was -1.4 kg whereas it was doubled in those on combination therapy (-2.4 kg). Although this study is small and hypothesis-generating, it suggests that these two drugs may be additive for weight loss. The effects of combination therapy on HbA1c need further study

McGovern et al. Diabetes UK Professional Conference. March 11–13, 2015; London, UK. Abstract A6 (P143).